Filtered By:
Condition: Hypertension
Drug: Coumadin
Education: Study

This page shows you your search results in order of relevance. This is page number 4.

Order by Relevance | Date

Total 156 results found since Jan 2013.

Cost‐Effectiveness of High‐Dose Edoxaban Compared with Adjusted‐Dose Warfarin for Stroke Prevention in Non–Valvular Atrial Fibrillation Patients
ConclusionsHigh‐dose edoxaban appears to be an economically dominant strategy when compared with adjusted‐dose warfarin for the prevention of stroke in NVAF patients with a Clcr of 15–95 ml/minute and an appreciable risk of stroke.
Source: Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy - April 26, 2016 Category: Drugs & Pharmacology Authors: Elaine Nguyen, Florence Egri, Elizabeth S. Mearns, Charles M. White, Craig I. Coleman Tags: Original Research Article Source Type: research

Reply Comparing the ATRIA, CHADS 2 , and CHA 2 DS 2 -VASc Scores for Stroke Prediction in Atrial Fibrillation
We tested the ATRIA (Anticoagulation and Risk Factors in Atrial Fibrillation), CHADS2 (congestive heart failure, hypertension, age ≥75 years, diabetes mellitus, stroke), and CHA2DS2-VASc (congestive heart failure, hypertension, age ≥75 years, diabetes mellitus, prior stroke or transient ischemic attack, vascular disease, age 65 to 74 years, female) stroke risk scores in the CPRD (Clinical Practice Research Datalink) cohort of incident atrial fibrillation (AF) patients not using oral anticoagulants (OAC) because these are the patients for whom physicians must make the OAC treatment decision (1). The mean patient follo...
Source: Journal of the American College of Cardiology - May 10, 2016 Category: Cardiology Source Type: research

Risk of Ischemic Stroke in High Risk Atrial Fibrillation Patients during Periods of Warfarin Discontinuation for Surgical Procedures
Importance: The risk of ischemic stroke during periods of warfarin discontinuation for surgical procedures is recognized but not well characterized. Objective: The study aimed to quantitate the risk of ischemic stroke associated with high risk atrial fibrillation during periods of warfarin discontinuation. Design, Setting and Participants: A cohort of 4,060 patients (mean follow-up period of 3.5 ± 1.3 years) were randomized into the Atrial Fibrillation Follow-Up Investigation of Rhythm Management study. Patients enrolled in the study had atrial fibrillation plus at least one other risk factor for stroke or death: age ≥6...
Source: Cerebrovascular Diseases - June 20, 2016 Category: Neurology Source Type: research

Stroke risks and patterns of warfarin therapy among atrial fibrillation patients post radiofrequency ablation: A real-world experience
In this study, we analyzed the stroke risks of patients who had undergone RFA for AF at our hospital between March 2014 and June 2016 using the CHADS2, CHADS2-VASc, and Hypertension, Abnormal renal/liver function, Stroke, Bleeding history or predisposition, Labile international normalized ratio, Elderly (> 65 years) (HAS-BLED) scoring systems. We retrieved medications, co-morbidities, and initial warfarin dosage data. The primary outcome was the percentage of patients initiated with warfarin therapy for stroke prophylaxis in AF who had a CHADS2-VASc score of 0. Totally, 309 patients were initiated with warfarin therapy ...
Source: Medicine - November 1, 2017 Category: Internal Medicine Tags: Research Article: Observational Study Source Type: research

Novel Oral Anticoagulants for the Prevention of Stroke in Patients with Atrial Fibrillation and Hypertension: A Meta-Analysis
ConclusionsOur findings suggest that NOACs can be recommended for the prevention of stroke or systemic embolism in patients with AF and hypertension.
Source: American Journal of Cardiovascular Drugs - March 31, 2019 Category: Cardiology Source Type: research

Incidence of stroke, systemic embolism and bleeding events in patients without anticoagulation based on real-world data in Japan: a retrospective cohort study
Conclusions Approximately one-third of the patients do not receive any anticoagulation in the modern DOAC era in Japan. The SSE rate increases by the CHADS2 score. The SSE rate is low in patients with a CHADS2 score <1, supporting no indication of anticoagulation in current guidelines. In patients with a CHADS2 score >1, the use of anticoagulant drug therapy is recommended because of a higher risk of stroke.
Source: BMJ Open - November 10, 2022 Category: General Medicine Authors: Tanizawa, K., Nishimura, Y., Sera, S., Yaguchi, D., Okada, A., Nishikawa, M., Tamaru, S., Nagai, N. Tags: Open access, Epidemiology Source Type: research

Screening for Asymptomatic Atrial Fibrillation While Monitoring the Blood Pressure at Home: Trial of Regular Versus Irregular Pulse for Prevention of Stroke (TRIPPS 2.0)
In conclusion, home screening for asymptomatic AF while taking BP measurements can be performed accurately. This can be used to detect new AF, allowing treatment with anticoagulation to reduce the future risk for stroke.
Source: The American Journal of Cardiology - March 18, 2013 Category: Cardiology Authors: Joseph Wiesel, Saji Abraham, Frank C. Messineo Tags: Arrhythmias and Conduction Disturbances Source Type: research

Real ‐World Clinical Characteristics and Treatment Patterns of Individuals Aged 80 and Older with Nonvalvular Atrial Fibrillation: Results from the ReAl‐life Multicenter Survey Evaluating Stroke Study
ConclusionNearly one‐fifth of individuals with NVAF in this real‐world sample were aged 80 and older. Participants aged 80 and older were more likely to be female and have more comorbidities than those who were younger than 80. Those aged 80 and older with AF were less likely to receive anticoagulants than those who were younger than 80, but having more comorbidities and other individual‐level characteristics may explain this difference. When they were prescribed OACs, participants aged 80 and older had poorer quality of anticoagulation than those who were younger, suggesting opportunities for improvement.
Source: Journal of the American Geriatrics Society - April 10, 2017 Category: Geriatrics Authors: Murat Biteker, Özcan Başaran, Volkan Doğan, İbrahim Altun, Fatma Özpamuk Karadeniz, Ahmet İlker Tekkesin, Yasin Çakıllı, Ceyhan Türkkan, Mehmet Hamidi, Vahit Demir, Mustafa Ozan Gürsoy, Müjgan Tek Öztürk, Gökhan Aksan, Sabri Seyis, Mehmet B Tags: Clinical Investigation Source Type: research

INR optimization based on stroke risk factors in patients with non-valvular atrial fibrillation
Conclusion The intensity of anticoagulation therapy for Korean patients with NVAF is optimal when INR is between 1.7 and 2.2.
Source: International Journal of Clinical Pharmacy - June 12, 2015 Category: Drugs & Pharmacology Source Type: research

Long ‐term aspirin does not lower risk of stroke and increases bleeding risk in low risk atrial fibrillation ablation patients
Conclusions: After catheter ablation, low risk patients do not benefit from long‐term aspirin therapy, but are at risk for higher rates of bleeding when compared to no therapy or warfarin.This article is protected by copyright. All rights reserved
Source: Journal of Cardiovascular Electrophysiology - August 1, 2017 Category: Cardiology Authors: Victoria Jacobs, Heidi T. May, Tami L. Bair, Brian G. Crandall, Michael J. Cutler DO, John D. Day, Charles Mallender, Jeffrey S. Osborn, J. Peter Weiss, T. Jared Bunch Tags: ORIGINAL ARTICLE Source Type: research

Prognostic significance of delayed intraventricular haemorrhage in the INTERACT studies
Conclusions Although linked to factors determining greater ICH growth including poor SBP control, dIVH is independently associated with poor outcome in acute small to moderate-size ICH. Trial registration numbers NCT00226096 and NCT00716079.
Source: Journal of Neurology, Neurosurgery and Psychiatry - December 14, 2016 Category: Neurosurgery Authors: Moullaali, T. J., Sato, S., Wang, X., Rabinstein, A. A., Arima, H., Carcel, C., Chen, G., Robinson, T., Heeley, E., Chan, E., Delcourt, C., Stapf, C., Cordonnier, C., Lindley, R. I., Chalmers, J., Anderson, C. S., for the INTERACT Investigators Tags: Stroke, Hypertension Cerebrovascular disease Source Type: research

Long ‐term aspirin does not lower risk of stroke and increases bleeding risk in low‐risk atrial fibrillation ablation patients
ConclusionsAfter catheter ablation, low risk patients do not benefit from long‐term aspirin therapy, but are at risk for higher rates of bleeding when compared to no therapy or warfarin.
Source: Journal of Cardiovascular Electrophysiology - September 26, 2017 Category: Cardiology Authors: Victoria Jacobs, Heidi T. May, Tami L. Bair, Brian G. Crandall, Michael J. Cutler DO, John D. Day, Charles Mallender, Jeffrey S. Osborn, J. Peter Weiss, T. Jared Bunch Tags: ORIGINAL ARTICLE Source Type: research

New Data From Two Large Studies Reinforce Effectiveness of Dual Pathway Inhibition (DPI) with XARELTO ® (rivaroxaban) Plus Aspirin in Patients with Coronary Artery Disease (CAD) and/or Peripheral Artery Disease (PAD)
RARITAN, N.J., May 23, 2022 – Findings from the XARELTO® (rivaroxaban) Phase 3 COMPASS Long-Term Open Label Extension (LTOLE) study and the XARELTO® in Combination with Acetylsalicylic Acid (XATOA) registry have been published in the European Society of Cardiology’s (ESC) European Heart Journal, Cardiovascular Pharmacotherapy. Additionally, the XATOA registry was presented at the American Congress of Cardiology’s 71st Annual Scientific Session (ACC.22). These studies provide further evidence supporting the role of dual pathway inhibition (DPI) with the XARELTO® vascular dose (2.5 mg twice daily plus aspirin 100 mg...
Source: Johnson and Johnson - May 23, 2022 Category: Pharmaceuticals Source Type: news

Pharmacological interventions for asymptomatic carotid stenosis
CONCLUSIONS: Although there is no high-certainty evidence to support pharmacological intervention, this does not mean that pharmacological treatments are ineffective in preventing ischaemic cerebral events, morbidity, and mortality. High-quality RCTs are needed to better inform the best medical treatment that may reduce the burden of carotid stenosis. In the interim, clinicians will have to use other sources of information.PMID:37565307 | DOI:10.1002/14651858.CD013573.pub2
Source: Atherosclerosis - August 11, 2023 Category: Cardiology Authors: Caroline Nb Clezar Carolina Dq Flumignan Nicolle Cassola Luis Cu Nakano Virginia Fm Trevisani Ronald Lg Flumignan Source Type: research